EUVIMEDSkopri EUVIMED
Crossref

Drug‐likeness evaluation and inhibitory mechanism of the emodin derivative on cardiac fibrosis based on metastasis‐associated protein 3

Heng Liu, Runze Li, Zhixia Wang, Weina Han, Xiuxiu Sun, Xinxin Dong, Han Lou, Run Xu, Ange Hu, Denis Baranenko, Xue Bai, Dan Xiao iD and 1 more

British Journal of Pharmacology · 2025

DOI: 10.1111/bph.70012 ↗

At a glance

Journal article in British Journal of Pharmacology, 2025. Written by Heng Liu and 12 co-authors. Institution: Pharmaceutical Experiment Teaching Center, College of Pharmacy, Harbin Medical University, Harbin, China. Major MEDLINE topics: Emodin. Cited 4 times so far (Crossref); 35 references. Funded by: National Natural Science Foundation of China.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Background and Purpose Emodin inhibits cardiac fibrosis through metastasis‐associated protein 3 (MTA3), but its limited bioavailability hinders clinical application. To enhance emodin's clinical potential, a new derivative, emodin succinyl ethyl ester, was synthesised by modifying the 3′‐OH position. This study assessed its drug‐likeness, anti‐fibrotic properties and molecular mechanisms involving MTA3. Experimental Approach Drug‐likeness properties of the emodin derivative were evaluated using computational‐aided drug design (CADD). Transverse aortic constriction (TAC)‐induced cardiac fibrosis and Angiotensin II (Ang II)‐stimulated cardiac fibroblasts were used in vivo and ex vivo, respectively, to determine the effects of the emodin derivative on cardiac fibrosis and fibroblast transdifferentiation. Bioinformatics analysis, CADD, chromatin immunoprecipitation (ChIP), luciferase reporter assays and functional experiments were employed to predict, identify and validate the relationship between MTA3 and its upstream transcription factors. Key Results The emodin derivative exhibited superior drug‐likeness and anti‐fibrotic effects compared to emodin by effectively inhibiting cardiac fibroblast transdifferentiation and restored MTA3 expression. E2F1 was identified and validated as a transcriptional regulator, promoting α‐SMA and COL1A2 expression, and directly reducing MTA3 expression in cardiac fibroblasts. The emodin derivative demonstrated stronger binding to the E2F1 transcription site than emodin, reducing E2F1 expression and enhancing anti‐fibrotic action. Conclusions and Implications The emodin derivative shows improved drug‐likeness and potent inhibition of cardiac fibrosis by targeting E2F1, disrupting its pro‐fibrotic function, restoring MTA3 expression and halting fibrosis progression. This advances emodin derivative's potential as a clinical therapy for cardiac fibrosis and provides insights into its anti‐fibrotic mechanisms.

Subjects

MeSH terms (MEDLINE)

EmodinAnimalsFibrosisMaleRatsFibroblastsRats, Sprague-DawleyCell TransdifferentiationCells, CulturedMyocardiumHumans

Author keywords

CADDEmodin derivativeMTA3cardiac fibrosis

Substances

Emodin

Authors and institutions

  • Pharmaceutical Experiment Teaching Center, College of Pharmacy, Harbin Medical University, Harbin, China.
  • National and Local Joint Engineering Laboratory for Synthesis Transformation and Separation of Extreme Environmental Nutrients, Harbin Institute of Technology, Harbin, Heilongjiang, China.
  • Zhengzhou Research Institute, Harbin Institute of Technology, Zhengzhou, Henan, China.
  • Department of Pharmacy, the fourth people's hospital of Datong, Shanxi, China.
  • School of Life Sciences, Faculty of Ecotechnologies, ITMO University, St. Petersburg, Russia.
  • Key Laboratory of Tropical Biological Resources of Ministry of Education, School of Pharmaceutical Sciences Hainan University, Haikou, China.

ORCID profiles: Dan Xiao

Funding

  • National Natural Science Foundation of China

Cite

APA

Liu, H., Li, R., Wang, Z., Han, W., Sun, X., Dong, X., Lou, H., Xu, R., Hu, A., Baranenko, D., Bai, X., Xiao, D., & Lu, W. (2025). Drug‐likeness evaluation and inhibitory mechanism of the emodin derivative on cardiac fibrosis based on metastasis‐associated protein 3. British Journal of Pharmacology. https://doi.org/10.1111/bph.70012

Vancouver

Liu H, Li R, Wang Z, Han W, Sun X, Dong X, et al. Drug‐likeness evaluation and inhibitory mechanism of the emodin derivative on cardiac fibrosis based on metastasis‐associated protein 3. British Journal of Pharmacology. 2025. doi:10.1111/bph.70012

BibTeX
@article{Liu2025,
  author = {Liu, Heng and Li, Runze and Wang, Zhixia and Han, Weina and Sun, Xiuxiu and Dong, Xinxin and Lou, Han and Xu, Run and Hu, Ange and Baranenko, Denis and Bai, Xue and Xiao, Dan and Lu, Weihong},
  title = {Drug‐likeness evaluation and inhibitory mechanism of the emodin derivative on cardiac fibrosis based on metastasis‐associated protein 3},
  journal = {British Journal of Pharmacology},
  year = {2025},
  doi = {10.1111/bph.70012}
}
Start for free →